Category

HTTP 200 OK
Allow: GET, HEAD, OPTIONS
Content-Type: application/json
Vary: Accept

{
    "count": 47,
    "next": "http://api.gregory-ms.com/categories/?format=api&page=5",
    "previous": "http://api.gregory-ms.com/categories/?format=api&page=3",
    "results": [
        {
            "category_id": 40,
            "category_description": "Autologous hematopoietic stem cell transplantation\n\nSearch terms: ahsct,Autologous hematopoietic stem cell transplantation,Bone marrow,Mesenchymal stem cells,Immunoablation",
            "category_name": "aHSCT",
            "category_slug": "ahsct",
            "category_terms": [
                "ahsct",
                "Autologous hematopoietic stem cell transplantation",
                "Bone marrow",
                "Immunoablation"
            ],
            "article_count": 90
        },
        {
            "category_id": 41,
            "category_description": "Sanofi has reported positive new data from a mid-stage study of its investigational anti-CD40L antibody in patients with relapsing multiple sclerosis (MS).\n\nResults from the phase 2 study, being presented at the 2023 Consortium of Multiple Sclerosis Centers annual meeting, demonstrate that frexalimab significantly reduced disease activity in patients with relapsing forms of the disease.\n\nSource: https://www.sanofi.com/en/media-room/press-releases/2023/2023-05-31-05-00-00-2678991",
            "category_name": "Frexalimab",
            "category_slug": "frexalimab",
            "category_terms": [
                "frexalimab",
                "SAR441344"
            ],
            "article_count": 2
        },
        {
            "category_id": 42,
            "category_description": "Foralumab",
            "category_name": "Foralumab",
            "category_slug": "foralumab",
            "category_terms": [
                "Foralumab",
                "TZLS-401"
            ],
            "article_count": 0
        },
        {
            "category_id": 43,
            "category_description": "Lipoic Acid",
            "category_name": "Lipoic Acid",
            "category_slug": "lipoic-acid",
            "category_terms": [
                "Lipoic acid"
            ],
            "article_count": 7
        },
        {
            "category_id": 11,
            "category_description": "Based on the following article, this item was added to the Observatory page.\r\n\r\n> Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial\r\n\r\nSource [The Lancet](https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(21)00237-4/fulltext)",
            "category_name": "Tolebrutinib",
            "category_slug": "tolebrutinib",
            "category_terms": [
                "tolebrutinib",
                "SAR442168"
            ],
            "article_count": 3
        },
        {
            "category_id": 1,
            "category_description": "Fingolimod, also known as Gilenya is a type of medicine known as a ‘disease-modifying therapy’ that is used to treat adults and children over 10 years of age with highly active relapsing-remitting multiple sclerosis (MS), a disease of the nerves in which inflammation destroys the protective sheath surrounding the nerve cells. ‘Relapsing-remitting’ means that the patient has flare-ups of symptoms (relapses) followed by periods of recovery (remissions). Gilenya is used when the disease remains active despite appropriate treatment with at least one other disease-modifying therapy, or is severe and getting worse rapidly.\r\n\r\nhttps://www.ema.europa.eu/en/medicines/human/EPAR/gilenya",
            "category_name": "Fingolimod",
            "category_slug": "fingolimod",
            "category_terms": [
                "fingolimod",
                "gilenya"
            ],
            "article_count": 259
        },
        {
            "category_id": 5,
            "category_description": "Tecfidera is a medicine used to treat multiple sclerosis (MS), a disease in which inflammation damages the protective insulation around nerves (demyelination) as well as the nerves themselves. It is used in adults and children from 13 years of age with a type of MS known as relapsing-remitting MS, where the patient has flare-ups of symptoms (relapses) followed by periods of recovery (remissions).\r\n\r\nTecfidera contains the active substance dimethyl fumarate.\r\n\r\nhttps://www.ema.europa.eu/en/medicines/human/EPAR/tecfidera",
            "category_name": "Tecfidera",
            "category_slug": "tecfidera",
            "category_terms": [
                "tecfidera",
                "dimethyl fumarate"
            ],
            "article_count": 162
        },
        {
            "category_id": 14,
            "category_description": "Aubagio is a medicine that contains the active substance teriflunomide. It is used to treat patients from the age of 10 years with multiple sclerosis (MS), a disease in which inflammation destroys the protective sheath around the nerves. \r\n\r\nAubagio is used in the type of MS known as relapsing-remitting MS, when the patient has flare-ups of symptoms (relapses) followed by periods of recovery (remissions).",
            "category_name": "Aubagio",
            "category_slug": "aubagio",
            "category_terms": [
                "teriflunomide",
                "aubagio"
            ],
            "article_count": 106
        },
        {
            "category_id": 19,
            "category_description": "Novantrone, mitoxantrone",
            "category_name": "Novantrone",
            "category_slug": "novantrone",
            "category_terms": [
                "Novantrone",
                "mitoxantrone"
            ],
            "article_count": 26
        },
        {
            "category_id": 34,
            "category_description": "Briumvi is a medicine for treating adults with relapsing forms of multiple sclerosis (a disease of the brain and spinal cord in which inflammation destroys the protective covering around nerves and damages the nerves), where the patient has flare-ups (relapses) followed by periods with milder or no symptoms. It is used in patients with active disease, which means that they have relapses and/or signs of active inflammation on scans.",
            "category_name": "Ublituximab",
            "category_slug": "ublituximab",
            "category_terms": [
                "ublituximab",
                "briumvi"
            ],
            "article_count": 10
        }
    ]
}